

Calliditas and Everest Medicines Enter into a Licensing Agreement for Nefecon in Greater China and Singapore for up to \$121 million

Torreya served as financial advisor to Calliditas Therapeutics AB

Stockholm, Sweden and Shanghai, China, June 10, 2019

Calliditas Therapeutics AB (STO: CALTX), a specialty pharmaceutical company, and Everest Medicines II Limited, a CBC Group-backed biopharmaceutical company, entered into a licensing agreement to develop and commercialize Calliditas' Nefecon for chronic autoimmune kidney disease IgA Nephropathy (IgAN) in Greater China and Singapore.

Under the terms of the agreement, Calliditas will receive an initial upfront payment of \$15 million, as well as up to \$106 million in development, regulatory and commercialization milestones. The agreement also includes an option worth up to \$20 million for the development of Nefecon in other potential indications. Everest will also pay typical royalties on net sales.

The partnership with Everest Medicines will help Calliditas to expand Nefecon's market reach to China, where there is a significant unmet medical need for this indication. Calliditas is currently running a pivotal, global Phase 3 clinical trial with Nefecon for the treatment of patients with IgAN. While IgAN is an orphan disease in the US and Europe, the prevalence is much higher in China, where IgAN is the most common primary glomerulonephritis and accounts for about 40% of primary glomerular diseases.

Torreya served as financial advisor to Calliditas in this transaction. This transaction reinforces Torreya's strength and leadership position as an advisor to biotechnology companies. This deal represents Torreya's 10th transaction in 2019 and 7th transaction involving a China party since 2018.

ABOUT CALLIDITAS THERAPEUTICS AB

For more information about Calliditas, please see: www.calliditas.se/en

ABOUT EVEREST MEDICINES II LIMITED

For more information about Everest Medicines, please see: www.everestmedicines.com

Deal Press Release

Torreya Contact

JIE LIU

Managing Director | New York Office

jie.liu@torreya.com | 917.683.4003 | torreya.com



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.